Compounded semaglutide gets talked about as if it were simply Ozempic or Wegovy from a different shelf. The FDA says it isn't. This page explains what "compounded" means, how it differs from the approved medicines, why dose mix-ups happen, and what to ask before you use it. Everything here comes from the FDA's own pages.
1.What does "compounded" mean?
A compounded drug is made by a pharmacy for an individual patient, based on a prescription (FDA). Think of a custom order, not a factory batch.
Approved medicines go through the FDA's review for safety, effectiveness and quality before they are sold. Compounded drugs don't.
“A compounded drug might be appropriate if a patient’s medical need cannot be met by an FDA-approved drug, or the FDA-approved drug is not commercially available. However, compounded drugs are not FDA approved. This means the agency does not review compounded drugs for safety, effectiveness or quality before they are marketed.”
2.Is compounded semaglutide the same as Ozempic or Wegovy?
No. The FDA lists a company that "makes claims such as the compounded drug is the same as an FDA-approved drug" as a warning sign (FDA). Two differences the FDA points to:
- Salt forms. Some compounders may use semaglutide sodium or semaglutide acetate. The FDA says these salt forms "are different active ingredients than are used in the approved drugs," which contain the base form of semaglutide. It also says it doesn't have information on whether the salts have the same chemical and pharmacologic properties (FDA).
- Added ingredients. Some compounders add vitamin B12, vitamin B6, L-carnitine or NAD. The FDA says the safety and effectiveness of combining semaglutide with other ingredients "has not been established" (FDA dosing alert, footnote 1).
3.Is there still a semaglutide shortage?
Not according to the FDA. It determined that the tirzepatide injection shortage was resolved on December 19, 2024, and the semaglutide injection shortage on February 21, 2025. In its April 1, 2026 update, the FDA said tirzepatide and semaglutide do not appear on its drug shortage list (FDA).
Why that matters: when an approved drug isn't in shortage, the FDA generally treats it as commercially available, and the law limits pharmacies from making what are essentially copies of it "regularly or in inordinate amounts." The rules for compounders can change, so this page sticks to what the FDA has published.
4.Why do dose mix-ups happen with compounded shots?
Approved semaglutide injections are dosed in milligrams, have standard concentrations and come in pre-filled pens. Compounded versions may come in multiple-dose vials or prefilled syringes, and the concentration can differ from one compounder to the next (FDA dosing alert).
Concentration is how much medicine is dissolved in each milliliter of liquid. Picture juice mixed strong or weak: the same size glass holds more juice when the mix is stronger.
A "unit" on an insulin syringe is a measure of liquid, not of medicine. In the FDA's example, 5 units on a U-100 (1 milliliter) syringe is 0.05 milliliter. How much semaglutide is in that liquid depends on the concentration. So the same number of units can mean a different amount of medicine from a different vial.
- What the FDA saw. In most reports, people drew up more than the prescribed dose and took five to 20 times more than intended. In some, people told to take 5 units took 50.
- It isn't only patients. Several reports describe health care providers miscalculating a dose when converting milligrams to units or milliliters.
- What was reported afterwards. Nausea, vomiting, abdominal pain, fainting, headache, migraine, dehydration, acute pancreatitis and gallstones. Some people needed hospital care.
“FDA encourages patients to talk with their health care provider or compounder about how to measure and administer the intended dose of compounded semaglutide.”
5.What should I ask before I use it?
- What exactly is the active ingredient? Is it the base form of semaglutide or a salt form? Is anything else added?
- What is the concentration? And what is my dose in milligrams, in milliliters and in the units on my syringe?
- Is this the right size syringe for my dose? The FDA encourages providers and compounders to supply the appropriate syringe and to show patients how to measure with it.
- Is the pharmacy state-licensed? You can look it up in your state board of pharmacy's database through FDA BeSafeRx. The FDA says that if a pharmacy isn't listed, you should not use it.
- Who do I call with questions? The FDA says to contact the compounder or the telehealth platform about instructions for use or anything on the label, and to talk to your doctor about your medicines.
6.How should a vial be handled?
- 28 days. The FDA recommends discarding a multiple-dose vial within 28 days after first use, even if medicine is left, and even if the compounder's instructions say it can be used longer. The risk of contamination goes up after 28 days.
- A new needle every time. Always use a new, sterile needle and syringe for each dose.
- Arrived warm? The FDA recommends not using any injectable GLP-1 that arrives warm or without enough refrigeration, because that can affect its quality.
Source for all three: FDA.
7.What are the FDA's red flags?
The FDA tells people to watch for a company that:
- says its compounded drug is the same as an FDA-approved drug
- offers deep discounts or prices that seem too good to be true
- doesn't require a screening and prescription from a licensed doctor
- has no licensed doctor available to answer questions after the medicine arrives
- sends medicine that looks different from what you've had before, or that arrives damaged or without instructions
- has spelling errors on the label, or a wrong pharmacy address
The FDA also says it is aware of fraudulent compounded semaglutide and tirzepatide with false information on the label, in some cases naming pharmacies that don't exist. And it urges people not to buy products labeled "for research purposes" or "not for human consumption," which it says are sold illegally and are of unknown quality (FDA).
8.How do I report a problem?
The FDA encourages patients to report side effects or quality problems to MedWatch, online or with a form faxed to 1-800-FDA-0178. Tell your prescriber too.
How Checkin helps
Checkin is a free AI companion for GLP-1s that you text. For this part of life on a GLP-1, it does three things:
- Ask about your medicine
Plain answers from that medicine's FDA label, with a picture when it helps.
- Text “took my shot”
It's logged, so your shot history is in one place.
- It checks in two days after your shot
A quick text to see how you're feeling.


